C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes Position in Illumina, Inc. (NASDAQ:ILMN)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 3,352 shares of the life sciences company's stock, valued at approximately $448,000.

Several other institutional investors also recently made changes to their positions in ILMN. WCM Investment Management LLC boosted its position in shares of Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after buying an additional 867,673 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Illumina by 148.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company's stock worth $137,735,000 after buying an additional 631,294 shares in the last quarter. Janus Henderson Group PLC raised its stake in Illumina by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock valued at $282,735,000 after purchasing an additional 625,245 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in Illumina by 116.9% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company's stock valued at $115,663,000 after purchasing an additional 466,519 shares during the last quarter. Finally, Iron Triangle Partners LP acquired a new position in Illumina in the 3rd quarter valued at about $57,380,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ILMN has been the subject of several analyst reports. Royal Bank of Canada cut their target price on shares of Illumina from $250.00 to $247.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Canaccord Genuity Group dropped their price objective on shares of Illumina from $145.00 to $135.00 and set a "hold" rating for the company in a research note on Friday, February 7th. JPMorgan Chase & Co. upped their price objective on shares of Illumina from $125.00 to $140.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Stephens upped their price objective on shares of Illumina from $170.00 to $184.00 and gave the company an "overweight" rating in a research note on Tuesday, November 12th. Finally, Citigroup downgraded shares of Illumina from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $159.45.

Illumina Stock Down 3.1 %

NASDAQ ILMN traded down $3.00 on Friday, reaching $94.20. The company had a trading volume of 4,225,715 shares, compared to its average volume of 2,990,509. The firm has a market capitalization of $14.92 billion, a PE ratio of -12.27, a P/E/G ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a 1 year low of $93.50 and a 1 year high of $156.66. The firm has a 50-day moving average of $127.98 and a 200-day moving average of $134.01. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.